It is easy to be cynical about announcements of drugs that claim to slow the progress of Alzheimer’s disease, the most common form of . Lecanemab, however, may be the real deal.

Read more: https://www.economist.com/science-and-technology/2022/11/30/a-drug-for-alzheimers-disease-that-seems-to-work